The stock of Sarepta Therapeutics Inc. (NASDAQ:SRPT) last traded at $107.35, up 2.05% from the previous session.
Data from the available sources indicates that Sarepta Therapeutics Inc. (NASDAQ:SRPT) is covered by 20 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $223.00 and a low of $139.00, we find $180.00. Given the previous closing price of $105.19, this indicates a potential upside of 71.12 percent. SRPT stock price is now -8.78% away from the 50-day moving average and -13.03% away from the 200-day moving average. The market capitalization of the company currently stands at $9.72B.
In total, 4 analysts have assigned it a hold rating, and 14 have given it a buy rating. Brokers who have rated the stock have averaged $179.16 as their price target over the next twelve months.
With the price target maintained at $139, Evercore ISI recently Downgraded its rating from Outperform to In-line for Sarepta Therapeutics Inc. (NASDAQ: SRPT).
In other news, Mayo Stephen, Director sold 858 shares of the company’s stock on Nov 17. The stock was sold for $94,311 at an average price of $109.92. Upon completion of the transaction, the Director now directly owns 6,387 shares in the company, valued at $0.69 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 14, Director Chambers Michael Andrew bought 57,100 shares of the business’s stock. A total of $5,963,124 was incurred on buying the stock at an average price of $104.43. This leaves the insider owning 108,178 shares of the company worth $11.61 million. Insiders disposed of 13,587 shares of company stock worth roughly $1.46 million over the past 1 year. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SRPT stock. A new stake in Sarepta Therapeutics Inc. shares was purchased by BOXER CAPITAL, LLC during the first quarter worth $83,196,000. ARTISAN PARTNERS LIMITED PARTNERSHIP invested $47,037,000 in shares of SRPT during the first quarter. In the first quarter, CAPITAL RESEARCH GLOBAL INVESTORS acquired a new stake in Sarepta Therapeutics Inc. valued at approximately $28,549,000. MIZUHO MARKETS CAYMAN LP acquired a new stake in SRPT for approximately $27,890,000. REDMILE GROUP, LLC purchased a new stake in SRPT valued at around $24,862,000 in the second quarter. In total, there are 599 active investors with 89.10% ownership of the company’s stock.
With an opening price of $108.04 on Thursday morning, Sarepta Therapeutics Inc. (NASDAQ: SRPT) set off the trading day. During the past 12 months, Sarepta Therapeutics Inc. has had a low of $92.54 and a high of $159.89. As of last week, the company has a debt-to-equity ratio of 1.73, a current ratio of 4.60, and a quick ratio of 4.30. The fifty day moving average price for SRPT is $116.85 and a two-hundred day moving average price translates $123.44 for the stock.
The latest earnings results from Sarepta Therapeutics Inc. (NASDAQ: SRPT) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.27, beating analysts’ expectations of -$1.78 by 1.51. This compares to -$2.65 EPS in the same period last year. The company reported revenue of $261.24 million for the quarter, compared to $233.49 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 11.89 percent. For the current quarter, analysts expect SRPT to generate $278.25M in revenue.
Sarepta Therapeutics Inc.(SRPT) Company Profile
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children’s Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
